JMD Properties, a property management company, completed the acquisition of Stella Diagnostics, a molecular diagnostics-based organization focused on improving patient management strategies. Before the acquisition, an investor in biotech Keystone Capital provided the foundational seed capital for Stella Diagnostics. Financial terms were not disclosed. “Stella Diagnostics is confident that a move into the diagnostic sector of the biotech industry will be beneficial both to our investors and to all those suffering from serious esophageal disease which is an underserved and ever-growing patient population in the U.S. and abroad,” Daniel Wainstein, JMD Properties Chairman of the Board.